header logo image


Page 71«..1020..70717273..8090..»

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant…

May 9th, 2023 12:02 am

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) --  NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that results of a Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with idiopathic BAM with IBS-D were presented at Digestive Disease Week 2023.

Original post:
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant...

Read More...

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

May 9th, 2023 12:02 am

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

The rest is here:
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Read More...

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

May 9th, 2023 12:02 am

EMERYVILLE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences:

Excerpt from:
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

Read More...

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

May 9th, 2023 12:02 am

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023

Read the original here:
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Read More...

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

May 9th, 2023 12:02 am

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year

Continue reading here:
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

Read More...

Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 9th, 2023 12:02 am

VANCOUVER, British Columbia, May 08, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.

Go here to see the original:
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results

Read More...

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 9th, 2023 12:02 am

Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint

See the original post here:
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Read More...

Myriad Genetics Earns 2023 Great Place to Work Certification™

May 9th, 2023 12:02 am

SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work® certification for 2023.

Continued here:
Myriad Genetics Earns 2023 Great Place to Work Certification™

Read More...

Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

May 9th, 2023 12:02 am

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. The company’s first quarter 2023 financial results news release is expected to be available after 1:00 p.m. Pacific Time on May 15, 2023, and on its website.

View original post here:
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

Read More...

BioAtla to Participate in the JMP Securities Life Sciences Conference

May 9th, 2023 12:02 am

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the JMP Securities Life Sciences Conference, to be held in New York, NY, from May 15-16, 2023.

Go here to read the rest:
BioAtla to Participate in the JMP Securities Life Sciences Conference

Read More...

Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

May 9th, 2023 12:02 am

Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million

Read more here:
Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Read More...

Certara Reports First Quarter 2023 Financial Results

May 9th, 2023 12:02 am

Reiterates 2023 Financial Guidance Reiterates 2023 Financial Guidance

Here is the original post:
Certara Reports First Quarter 2023 Financial Results

Read More...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9th, 2023 12:02 am

MALVERN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 27,250 shares of its common stock to seventeen newly-hired employees, with a grant date of May 5, 2023 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

Read more from the original source:
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More...

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection…

May 9th, 2023 12:02 am

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model

Go here to see the original:
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection...

Read More...

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 9th, 2023 12:02 am

First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy

Link:
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

Read More...

From fear to freedom: Anchor Paul LaGrone shares his story of sudden hair loss & the disease that caused it – ABC Action News Tampa Bay

May 9th, 2023 12:01 am

From fear to freedom: Anchor Paul LaGrone shares his story of sudden hair loss & the disease that caused it  ABC Action News Tampa Bay

Follow this link:
From fear to freedom: Anchor Paul LaGrone shares his story of sudden hair loss & the disease that caused it - ABC Action News Tampa Bay

Read More...

Biotechnology – Applications of biotechnology | Britannica

May 1st, 2023 12:13 am

Biotechnology has numerous applications, particularly in medicine and agriculture. Examples include the use of biotechnology in merging biological information with computer technology (bioinformatics), exploring the use of microscopic equipment that can enter the human body (nanotechnology), and possibly applying techniques of stem cell research and cloning to replace dead or defective cells and tissues (regenerative medicine). Companies and academic laboratories integrate these disparate technologies in an effort to analyze downward into molecules and also to synthesize upward from molecular biology toward chemical pathways, tissues, and organs.

In addition to being used in health care, biotechnology has proved helpful in refining industrial processes through the discovery and production of biological enzymes that spark chemical reactions (catalysts); for environmental cleanup, with enzymes that digest contaminants into harmless chemicals and then die after consuming the available food supply; and in agricultural production through genetic engineering.

Agricultural applications of biotechnology have proved the most controversial. Some activists and consumer groups have called for bans on genetically modified organisms (GMOs) or for labeling laws to inform consumers of the growing presence of GMOs in the food supply. In the United States, the introduction of GMOs into agriculture began in 1993, when the FDA approved bovine somatotropin (BST), a growth hormone that boosts milk production in dairy cows. The next year, the FDA approved the first genetically modified whole food, a tomato engineered for a longer shelf life. Since then, regulatory approval in the United States, Europe, and elsewhere has been won by dozens of agricultural GMOs, including crops that produce their own pesticides and crops that survive the application of specific herbicides used to kill weeds.

Studies by the United Nations, the U.S. National Academy of Sciences, the European Union, the American Medical Association, U.S. regulatory agencies, and other organizations have found GMO foods to be safe, but skeptics contend that it is still too early to judge the long-term health and ecological effects of such crops. In the late 20th and early 21st centuries, the land area planted in genetically modified crops increased dramatically, from 1.7 million hectares (4.2 million acres) in 1996 to 180 million hectares (445 million acres) by 2014. By 201415 about 90 percent of the corn, cotton, and soybeans planted in the United States were genetically modified. The majority of genetically modified crops were grown in the Americas.

Overall, the revenues of U.S. and European biotechnology industries roughly doubled over the five-year period from 1996 through 2000. Rapid growth continued into the 21st century, fueled by the introduction of new products, particularly in health care. By 2020 the biotechnology market size was estimated at $752.88 billion globally, with new opportunities for growth emerging in particular from government- and industry-driven efforts to accelerate drug development and product-approval processes.

See the rest here:
Biotechnology - Applications of biotechnology | Britannica

Read More...

Where Does BioLine RX Ltd – ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? – InvestorsObserver

May 1st, 2023 12:13 am

Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week?  InvestorsObserver

See the original post:
Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver

Read More...

Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? – InvestorsObserver

May 1st, 2023 12:13 am

Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week?  InvestorsObserver

Original post:
Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver

Read More...

Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? – InvestorsObserver

May 1st, 2023 12:13 am

Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week?  InvestorsObserver

See more here:
Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver

Read More...

Page 71«..1020..70717273..8090..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick